Abstract 815P
Background
Incidence of metastatic endometrial carcinoma (EC) is increasing worldwide. Recent therapeutic innovations reinforce the need to better understand patients (pts) characteristics, treatment patterns and clinical outcome in the real-world setting.
Methods
Patients beginning 1st or 2nd line chemotherapy (chemo) during the year 2019 were included in this multicenter, retrospective cohort study and were followed until December 31, 2021 or death. Up to 9 pts were included in each of the 30 centers across France. Two hundred pts, 127 in 1st line (cohort 1) and 73 in 2nd line (cohort 2), were enrolled. Median age was 71 years (min: 39 max: 93) and 31 % were > 75 years old. Significant comorbidities included overweight (BMI > 25 kg/m2) in 49 % of pts, medically treated hypertension, diabetes mellitus and deep venous thrombosis in 28.5%, 14.5% and 11%, respectively. ECOG performance status was 2 or 3 in 12% of pts. Endometrioïd carcinoma was the most common histological subtype (62%), followed by serous carcinoma (22%) and carcinosarcoma (5%). One third of pts had a FIGO IVB disease. MMR status was available only in 34% of pts and 21% of them was deficient.
Results
In 1st line, most pts received carboplatin and paclitaxel association (79%) or other platinum-based combinations (17%). Median PFS and OS were 8.5 months (mos) (CI 95%: 6.3-10.5) and 13.2 mos (CI95%: 10.9-16.6), respectively. The presence of liver metastases was the main prognostic factor for PFS and OS. In 2nd line, data from pts in cohorts 1 (49% received 2nd line chemo during the follow-up period) and 2 were pooled (n=135). Anthracycline and weekly paclitaxel as a single agent were used in 52% and 10%, respectively while platinum-based protocol was used in 23% of patients. Median PFS and OS were 4.0 mos (CI95%: 3.5-5.3) and 9.6 mos (CI95%: 8.3-11.8), respectively. A 3rd line of chemo was administered to 78 pts (39%): 31% received gemcitabine and 17% a platinum-based combination. Median PFS was 2.6 mos (CI95%: 2.1-4.1).
Conclusions
In this real-life cohort, metastatic EC affected older and frail women and was associated with poor overall survival despite chemo. There is an urgent need of new therapeutics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ARCAGY-GINECO.
Funding
MSD.
Disclosure
J. Alexandre: Financial Interests, Personal, Advisory Board: Eisai, MSD, GSK, Janssen, Pfizer; Financial Interests, Personal, Invited Speaker: Eisai, MSD, AstraZeneca, GSK, Novartis; Financial Interests, Institutional, Research Grant: Janssen, GSK, MSD; Financial Interests, Institutional, Local PI: MSD, Eisai, Agenus, GSK, Immunogen, Incyte. E. Kalbacher: Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca, Eisai, GSK, Leopharma, Roche, Sanofi, Seagen, Tesaro, Viatris. B. Asselain: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre; Financial Interests, Personal, Advisory Role: AstraZeneca, Daiichi Sankyo, Gilead; Financial Interests, Personal, Training: Servier, Roche. S. Emambux: Financial Interests, Personal, Advisory Role: BMS, Eisai, Janssen; Financial Interests, Personal, Other, Travel: Pfizer, Chugai. G. Babin: Financial Interests, Personal, Advisory Role: MSD, GSK. C. Lescure: Non-Financial Interests, Personal, Other, attend congress ( ESMO 2022 ): Viatris; Non-Financial Interests, Personal, Other, attend congress ( St Paul de Vence 2022 & 2023): Lilly. P. Heudel: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Novartis, Seagen, Lilly, MSD, Gilead; Financial Interests, Personal, Ownership Interest: GeodAIsics. N. Delanoy: Financial Interests, Personal, Advisory Role: GSK, Clovis Oncology, Eisai. P. Combe: Financial Interests, Personal and Institutional, Advisory Board, + Investigator: AstraZeneca, BMS, MSD, Novartis; Financial Interests, Personal, Advisory Board: Eisai, Sanofi, Daiichi Sankyo, Clovis Oncology, GSK, Amgen. F. Selle: Financial Interests, Personal and Institutional, Advisory Role, + Clinical Trial: AstraZeneca, GSK, MSD; Financial Interests, Personal, Advisory Role: Novartis, Clovis Oncology; Financial Interests, Institutional, Other, Clinical Trial: Roche, Immunogen, Incyte, Agenus. A. Hakme, L. Cagnan: Financial Interests, Personal, Full or part-time Employment: MSD. S. De Percin: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11
812P - Mental and socioeconomic burden in co-parents and children of patients with endometrial and cervical cancer: A Swedish population-based study
Presenter: Karin Sundström
Session: Poster session 11
814P - Clinical significance of isolated pulmonary recurrence in patients with endometrioid endometrial cancer who achieved complete remission after primary treatment
Presenter: Jigeun Yoo
Session: Poster session 11
816P - Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Presenter: Alain Zeimet
Session: Poster session 11
817P - A systematic review of recruitment of ethnic minorities to RCTs of systemic anti-cancer therapies in gynaecological cancers
Presenter: Luke Steventon
Session: Poster session 11